SCYNEXIS' Announcement
SCYNEXIS (NASDAQ:SCYX) is a micro cap biotech company that develops novel anti-fungal treatments.
On Tuesday, July 24, the company announced that
it has reached an agreement with the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) on the design, trial population, endpoints and statistical analysis of the CANDLE study, its pivotal Phase 3 clinical trial of oral ibrexafungerp for the prevention of recurrent VVC.
This SPA provides agreement with the FDA that the Phase 3 protocol design adequately addresses efficacy objectives that, if met, would form the